Page 38 - Read Online

Page 6 of 6 Cheson. J Cancer Metastasis Treat 2022;8:8 https://dx.doi.org/10.20517/2394-4722.2021.153

lymphoma. J Clin Oncol 2017;35:3898-905. DOI PubMed
36. Flinn IW, Miller CB, Ardeshna KM, et al. DYNAMO: a phase II study of duvelisib (IPI-145) in patients with refractory indolent non-
Hodgkin lymphoma. J Clin Oncol 2019;37:912-22. DOI PubMed
37. Lunning M, Vose J, Nastoupil L, et al. Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic
lymphocytic leukemia. Blood 2019;134:1811-20. DOI PubMed PMC
38. Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or
refractory Hodgkin’s lymphoma. J Clin Oncol 2012;30:2183-9. DOI PubMed PMC
39. Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J
Med 2015;372:311-9. DOI PubMed PMC
40. Armand P, Kuruvilla J, Michot JM, et al. KEYNOTE-013 4-year follow-up of pembrolizumab in classical Hodgkin lymphoma after
brentuximab vedotin failure. Blood Adv 2020;4:2617-22. DOI PubMed PMC
41. Allen PB, Savas H, Evens AM, et al. Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical
Hodgkin lymphoma. Blood 2021;137:1318-26. DOI PubMed PMC
42. Evens AM, Advani RH, Helenowski IB, et al. Multicenter phase II study of sequential Brentuximab Vedotin and Doxorubicin,
Vinblastine, and Dacarbazine chemotherapy for older patients with untreated classical Hodgkin lymphoma. J Clin Oncol
2018;36:3015-22. DOI PubMed
43. Cheson BD, Bartlett NL, Laplant B, et al. Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-
ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2 trial. Lancet Haematol 2020;7:e808-15.
DOI PubMed
44. Salles G, Duell J, González Barca E, et al. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-
MIND): a multicentre, prospective, single-arm, phase 2 study. Lancet Oncol 2020;21:978-88. DOI PubMed
45. Caimi PF, Ai W, Alderuccio JP, et al. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a
multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol 2021;22:790-800. DOI PubMed
46. Kalakonda N, Maerevoet M, Cavallo F, et al. Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma
(SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial. Lancet Haematol 2020;7:e511-22. DOI PubMed
47. Hutchings M, Mous R, Clausen MR, et al. Subcutaneous Epcoritamab induces complete responses with an encouraging safety profile
across relapsed/refractory B-cell non-Hodgkin lymphoma subtypes, including patients with prior CAR-T therapy: updated dose
escalation data. Blood 2020;136:45-6. DOI
48. Hutchings M, Carlo-stella C, Bachy E, et al. Glofitamab step-up dosing induces high response rates in patients with hard-to-treat
refractory or relapsed non-Hodgkin lymphoma. Blood 2020;136:46-8. DOI
49. Assouline SE, Kim WS, Sehn LH, et al. Mosunetuzumab shows promising efficacy in patients with multiply relapsed follicular
lymphoma: updated clinical experience from a phase I dose-escalation trial. Blood 2020;136:42-4. DOI
50. Olszewski AJ, Avigdor A, Babu S, et al. Single-agent Mosunetuzumab is a promising safe and efficacious chemotherapy-free regimen
for elderly/unfit patients with previously untreated diffuse large B-cell lymphoma. Blood 2020;136:43-5. DOI
51. Neelapu SS, Dickinson M, Ulrickson ML, et al. Interim analysis of AZUMA-12: a phase 2 study of axicaptagene ciloleucel (Axi-Cel)
as first-line therapy in patients (pts) with high-risk large B cell lymphoma (LBCL). Available from:
https://ash.confex.com/ash/2020/webprogram/Paper134449.html [Last accessed on 3 Mar 2022].
52. Cheson BD. Follicular lymphoma: is the road to cure paved with GALLIUM? Available from: https://ascopost.com/issues/december-
10-2017/follicular-lymphoma-is-the-road-to-cure-paved-with-gallium/ [Last accessed on 3 Mar 2022].
53. Chapuy B, Stewart C, Dunford AJ, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic
mechanisms and outcomes. Nat Med 2018;24:679-90. DOI PubMed PMC
54. Schmitz R, Wright GW, Huang DW, et al. Genetics and pathogenesis of diffuse large B-cell lymphoma. N Engl J Med 2018;378:1396-
407. DOI PubMed PMC
55. Kurtz DM, Scherer F, Jin MC, et al. Circulating tumor DNA measurements as early outcome predictors in diffuse large B-cell
lymphoma. J Clin Oncol 2018;36:2845-53. DOI PubMed PMC
56. Meignan M, Cottereau AS, Versari A, et al. Baseline metabolic tumor volume predicts outcome in high-tumor-burden follicular
lymphoma: a pooled analysis of three multicenter studies. J Clin Oncol 2016;34:3618-26. DOI PubMed
57. Bolen CR, Klanova M, Trneny M, et al. Prognostic impact of somatic mutations in diffuse large B-cell lymphoma and relationship to
cell-of-origin: data from the phase III GOYA study. Haematologica 2020;105:2298-307. DOI PubMed PMC
58. Cheson BD. Predicting the future for DLBCL. Blood 2020;135:1308-9. DOI PubMed